Kerman University of Medical Sciences International Journal of Health Policy and Management 2322-5939 11 2 2022 02 01 Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study 218 223 3863 10.34172/ijhpm.2020.113 EN Haishaerjiang Wushouer Center for Strategic Studies, Chinese Academy of Engineering, Beijing, China School of Medicine, Tsinghua University, Beijing, China International Research Center for Medicinal Administration (IRCMA), Peking University, Beijing, China 0000-0003-1466-9840 Zhenhuan Luo Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China 0000-0002-3259-4005 Xiaodong Guan International Research Center for Medicinal Administration (IRCMA), Peking University, Beijing, China Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China 0000-0002-1290-3827 Luwen Shi International Research Center for Medicinal Administration (IRCMA), Peking University, Beijing, China Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China 0000-0003-2683-6685 Journal Article 2019 12 12 Background Chinese government established maximum retail prices for antibiotics listed in China’s National Reimbursement List in February 2013. This study aimed to analyze the impact of pharmaceutical price regulation on the price, volume and spending of antibiotics in China. Methods An interrupted time series design with comparison series was used to examine impacts of the policy changes on average daily cost, monthly hospital purchase volume and spending of the 11 price-regulated antibiotics and 40 priceunregulated antibiotics in 699 hospitals. One intervention point was applied to assess the impact of policy. Results After government price regulation, compared to price-unregulated antibiotics, the average daily cost of the price-regulated group declined rapidly (β = -5.68, P < .001). The average hospital monthly purchase spending of priceregulated antibiotics also decreased rapidly (β = -0.49, P < .010) and a positive trend change (β = 0.04, P < .001) in average hospital spending of price-unregulated antibiotics was found. Conclusion Government regulation can reduce the prices and spending of price-regulated antibiotics. To control increasing expenditure, besides price caps regulation, factors determining drug utilization also need to be considered in policy designing.

https://www.ijhpm.com/article_3863_c4d2ce3f3ebb5393a77c33c0cd95dc93.pdf